Anixa Biosciences (ANIX) Competitors $2.53 -0.21 (-7.66%) (As of 05:26 PM ET) Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrends ANIX vs. BTMD, DSGN, VYGR, CTNM, SLRN, KMDA, CGC, TRVI, AQST, and ETONShould you be buying Anixa Biosciences stock or one of its competitors? The main competitors of Anixa Biosciences include biote (BTMD), Design Therapeutics (DSGN), Voyager Therapeutics (VYGR), Contineum Therapeutics (CTNM), Acelyrin (SLRN), Kamada (KMDA), Canopy Growth (CGC), Trevi Therapeutics (TRVI), Aquestive Therapeutics (AQST), and Eton Pharmaceuticals (ETON). These companies are all part of the "pharmaceutical products" industry. Anixa Biosciences vs. biote Design Therapeutics Voyager Therapeutics Contineum Therapeutics Acelyrin Kamada Canopy Growth Trevi Therapeutics Aquestive Therapeutics Eton Pharmaceuticals biote (NASDAQ:BTMD) and Anixa Biosciences (NASDAQ:ANIX) are both small-cap medical companies, but which is the better investment? We will compare the two businesses based on the strength of their media sentiment, profitability, risk, community ranking, institutional ownership, earnings, analyst recommendations, valuation and dividends. Does the media prefer BTMD or ANIX? In the previous week, biote had 4 more articles in the media than Anixa Biosciences. MarketBeat recorded 5 mentions for biote and 1 mentions for Anixa Biosciences. Anixa Biosciences' average media sentiment score of 1.46 beat biote's score of 0.72 indicating that Anixa Biosciences is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment biote 1 Very Positive mention(s) 1 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Anixa Biosciences 1 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Which has more risk and volatility, BTMD or ANIX? biote has a beta of 1.07, indicating that its share price is 7% more volatile than the S&P 500. Comparatively, Anixa Biosciences has a beta of 0.82, indicating that its share price is 18% less volatile than the S&P 500. Do analysts prefer BTMD or ANIX? biote currently has a consensus price target of $9.11, indicating a potential upside of 47.41%. Anixa Biosciences has a consensus price target of $8.50, indicating a potential upside of 235.97%. Given Anixa Biosciences' stronger consensus rating and higher probable upside, analysts plainly believe Anixa Biosciences is more favorable than biote.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score biote 0 Sell rating(s) 0 Hold rating(s) 5 Buy rating(s) 0 Strong Buy rating(s) 3.00Anixa Biosciences 0 Sell rating(s) 0 Hold rating(s) 2 Buy rating(s) 1 Strong Buy rating(s) 3.33 Does the MarketBeat Community prefer BTMD or ANIX? Anixa Biosciences received 10 more outperform votes than biote when rated by MarketBeat users. However, 100.00% of users gave biote an outperform vote while only 70.59% of users gave Anixa Biosciences an outperform vote. CompanyUnderperformOutperformbioteOutperform Votes14100.00% Underperform VotesNo VotesAnixa BiosciencesOutperform Votes2470.59% Underperform Votes1029.41% Which has stronger earnings and valuation, BTMD or ANIX? biote has higher revenue and earnings than Anixa Biosciences. Anixa Biosciences is trading at a lower price-to-earnings ratio than biote, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratiobiote$193.06M1.74$3.32M$0.2623.77Anixa Biosciences$210K387.68-$9.81M-$0.39-6.49 Is BTMD or ANIX more profitable? biote has a net margin of 5.20% compared to Anixa Biosciences' net margin of 0.00%. biote's return on equity of -32.41% beat Anixa Biosciences' return on equity.Company Net Margins Return on Equity Return on Assets biote5.20% -32.41% 22.26% Anixa Biosciences N/A -54.79%-50.37% Do institutionals and insiders believe in BTMD or ANIX? 21.7% of biote shares are held by institutional investors. Comparatively, 29.1% of Anixa Biosciences shares are held by institutional investors. 13.9% of biote shares are held by insiders. Comparatively, 22.6% of Anixa Biosciences shares are held by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock will outperform the market over the long term. Summarybiote beats Anixa Biosciences on 11 of the 19 factors compared between the two stocks. Ad Crypto Swap ProfitsURGENT: This Altcoin Opportunity Won’t Wait – Act NowIt’s here. This is the moment we’ve been waiting for. The next 3-6 months in crypto will be absolutely life-changing for those who are prepared. Why? Because altcoin prices are about to explode.>> Register for the Workshop Now Get Anixa Biosciences News Delivered to You Automatically Sign up to receive the latest news and ratings for ANIX and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart ANIX vs. The Competition Export to ExcelMetricAnixa BiosciencesPharmaceutical IndustryMedical SectorNASDAQ ExchangeMarket Cap$81.41M$6.72B$5.04B$8.97BDividend YieldN/A3.07%4.81%4.06%P/E Ratio-6.4910.40133.0816.93Price / Sales387.68187.581,120.44116.20Price / CashN/A57.1640.6337.95Price / Book3.375.194.754.71Net Income-$9.81M$151.85M$118.34M$225.20M7 Day Performance-13.95%-7.93%11.87%-3.77%1 Month Performance-17.05%-1.49%11.93%4.45%1 Year Performance-31.99%12.16%31.39%18.66% Anixa Biosciences Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)ANIXAnixa Biosciences2.9539 of 5 stars$2.53-7.7%$8.50+236.0%-26.9%$81.41M$210,000.00-6.495Short Interest ↓BTMDbiote3.2916 of 5 stars$6.60+3.6%$9.11+38.0%+24.5%$358.62M$193.06M24.77194Analyst ForecastNews CoverageDSGNDesign Therapeutics0.8004 of 5 stars$6.29+12.3%$7.00+11.3%+144.1%$356.15MN/A-7.1840Positive NewsVYGRVoyager Therapeutics4.5817 of 5 stars$6.51+3.8%$17.00+161.1%-21.7%$355.64M$250.01M8.83100CTNMContineum Therapeutics1.8722 of 5 stars$13.68-2.5%$29.25+113.8%N/A$352.67M$50M0.0031SLRNAcelyrin2.7719 of 5 stars$3.38+4.6%$11.75+247.6%-55.6%$339.12MN/A-1.31135KMDAKamada4.141 of 5 stars$5.85-0.3%$14.50+147.9%-3.0%$336.26M$158.38M20.96360News CoveragePositive NewsCGCCanopy Growth2.3636 of 5 stars$3.07-1.3%$3.50+14.0%-41.2%$334.45M$220.27M-0.631,029Analyst DowngradeShort Interest ↓News CoverageTRVITrevi Therapeutics3.5454 of 5 stars$4.30+3.1%$9.31+116.6%+251.6%$330.54MN/A-10.2020High Trading VolumeAQSTAquestive Therapeutics1.607 of 5 stars$3.61flat$9.80+171.5%+92.5%$329.16M$50.58M-8.02160Analyst ForecastNews CoveragePositive NewsETONEton Pharmaceuticals3.0552 of 5 stars$12.72+3.0%$15.00+17.9%+184.0%$328.69M$31.64M-56.1420 Related Companies and Tools Related Companies biote Alternatives Design Therapeutics Alternatives Voyager Therapeutics Alternatives Contineum Therapeutics Alternatives Acelyrin Alternatives Kamada Alternatives Canopy Growth Alternatives Trevi Therapeutics Alternatives Aquestive Therapeutics Alternatives Eton Pharmaceuticals Alternatives Top 10 Stock Comparisons Bank Stocks Artificial Intelligence Stocks Toy Stocks Growth Stocks Airline Stocks Chinese Stocks EV Charging Stocks Defense Stocks Lithium Stocks Pharmaceutical Stocks This page (NASDAQ:ANIX) was last updated on 12/18/2024 by MarketBeat.com Staff From Our PartnersUncover the Top Gold Stock of the Bull MarketGold Stocks Are Surging—Is West Red Lake Gold Mines Your Next Profit Play?Huge Alerts | SponsoredURGENT: This Altcoin Opportunity Won’t Wait – Act NowCrypto has officially entered the "banana zone" – that wild phase where prices can 1000x in days. It happen...Crypto Swap Profits | SponsoredMissed Nvidia? Buy Elon Musk’s “Silent Partner”In February 2016, when almost nobody was talking about artificial intelligence… I picked Nvidia as one of my f...Brownstone Research | SponsoredMusk’s new company could top a trillion?The investment legend who predicted the rise of Bitcoin, Facebook and streaming services like Netflix… Just...Paradigm Press | SponsoredSeeing is believing… Today, I want to share all the details with you… and show you how to leverage this incredible wealth-building ...Porter & Company | SponsoredPlease don’t take this warning lightly…Something huge is about to hit the stock market. Wall St. legend Louis Navellier calls it: "The most signif...InvestorPlace | SponsoredWhy Buffett, Griffin and 100 members of Congress are Piling into this One InvestmentThis isn't just another investment. It might be the last retirement stock you'll ever need. But this win...Behind the Markets | SponsoredDid You See Trump’s Bombshell Exec. Order 001?Starting with what I call Exec. Order 001. It’s a bombshell law that I believe Trump will sign within minut...Banyan Hill Publishing | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Anixa Biosciences, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Anixa Biosciences With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Free ANIX Stock Alerts